Association of Serum Complement C3 Levels with Severity and Mortality in COVID 19
© The Author(s), under exclusive licence to Association of Clinical Biochemists of India 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law..
The severe acute respiratory distress syndrome-associated coronavirus-2 infection can activate innate and adaptive immune responses which may lead to harmful tissue damage, both locally and systemically. C3, a member of complement system of serum proteins, is a major component of innate immune and inflammatory responses. This study is aimed to assess serum C3 as a marker of COVID-19 severity and a predictor of disease progression. A total of 150 COVID-19 patients, confirmed by RT-PCR, and 50 healthy controls were recruited. Serum C3 levels were determined by using direct colorimetric method. Median levels of serum C3 in total cases and controls were 157.8 and 165.7 mg/dL respectively. Serum C3 although not significantly decreased, they were lower in cases when compared to controls. Similarly, significant differences were found between the groups, with severe group (140.6 mg/dL) having low levels of serum C3 protein when compared to mild (161.0 mg/dL) and moderate group (167.1 mg/dL). Interestingly, during hospitalization, significant difference between baseline (admission) and follow-up (discharge) was observed only in patients with moderate disease. Based on our results, lower levels of C3, with an increase in IL-6 and d-dimer levels, are associated with higher odds of mortality. Therefore, we would like to emphasize that measuring serum C3 levels along with other inflammatory markers might give an added advantage in early identification of patients who are prone to having a severe disease course and can help in a more effective follow-up of disease progression.
Supplementary Information: The online version contains supplementary material available at 10.1007/s12291-023-01148-x.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Indian journal of clinical biochemistry : IJCB - 38(2023), 4 vom: 18. Okt., Seite 447-456 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tomo, Sojit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 26.09.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s12291-023-01148-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362430144 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362430144 | ||
| 003 | DE-627 | ||
| 005 | 20231226091228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12291-023-01148-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362430144 | ||
| 035 | |a (NLM)37746543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tomo, Sojit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of Serum Complement C3 Levels with Severity and Mortality in COVID 19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), under exclusive licence to Association of Clinical Biochemists of India 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a The severe acute respiratory distress syndrome-associated coronavirus-2 infection can activate innate and adaptive immune responses which may lead to harmful tissue damage, both locally and systemically. C3, a member of complement system of serum proteins, is a major component of innate immune and inflammatory responses. This study is aimed to assess serum C3 as a marker of COVID-19 severity and a predictor of disease progression. A total of 150 COVID-19 patients, confirmed by RT-PCR, and 50 healthy controls were recruited. Serum C3 levels were determined by using direct colorimetric method. Median levels of serum C3 in total cases and controls were 157.8 and 165.7 mg/dL respectively. Serum C3 although not significantly decreased, they were lower in cases when compared to controls. Similarly, significant differences were found between the groups, with severe group (140.6 mg/dL) having low levels of serum C3 protein when compared to mild (161.0 mg/dL) and moderate group (167.1 mg/dL). Interestingly, during hospitalization, significant difference between baseline (admission) and follow-up (discharge) was observed only in patients with moderate disease. Based on our results, lower levels of C3, with an increase in IL-6 and d-dimer levels, are associated with higher odds of mortality. Therefore, we would like to emphasize that measuring serum C3 levels along with other inflammatory markers might give an added advantage in early identification of patients who are prone to having a severe disease course and can help in a more effective follow-up of disease progression | ||
| 520 | |a Supplementary Information: The online version contains supplementary material available at 10.1007/s12291-023-01148-x | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C3 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Complement system | |
| 650 | 4 | |a IL-6 | |
| 700 | 1 | |a Kiran Kumar, Pvsn |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Dharamveer |e verfasserin |4 aut | |
| 700 | 1 | |a Sankanagoudar, Shrimanjunath |e verfasserin |4 aut | |
| 700 | 1 | |a Charan, Jayakaran |e verfasserin |4 aut | |
| 700 | 1 | |a Purohit, Abhishek |e verfasserin |4 aut | |
| 700 | 1 | |a Nag, Vijaya Lakshmi |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatia, Pradeep Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Kuldeep |e verfasserin |4 aut | |
| 700 | 1 | |a Dutt, Naveen |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Mahendra Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Misra, Sanjeev |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Praveen |e verfasserin |4 aut | |
| 700 | 1 | |a Purohit, Purvi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of clinical biochemistry : IJCB |d 1996 |g 38(2023), 4 vom: 18. Okt., Seite 447-456 |w (DE-627)NLM086804820 |x 0970-1915 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:4 |g day:18 |g month:10 |g pages:447-456 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12291-023-01148-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 4 |b 18 |c 10 |h 447-456 | ||